Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: The Atlas of Health Care Variation CVD cohort (VIEW-1)

New Zealand Medical Journal

Volumn 127, Issue 1400, 2014, Pages 39-69

  Kerr, Andrew J ^a   Exeter, Dan ^a   Grey, Corina ^a   Jackson, Rod ^a   Riddell, Tania ^a   Wells, Sue ^a   Zhao, Jinfeng ^a   Hanham, Grant ^b   Lee, Mildred ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Hanham Consultants   (New Zealand)

^c Rheumatology Department   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR PROCEDURE; COHORT ANALYSIS; ETHNICITY; FEMALE; GENDER; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; SECONDARY PREVENTION; SOCIAL STATUS; CORONARY ARTERY DISEASE; DRUG COMBINATION; ETHNIC GROUP; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCRIPTION; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICS;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; CORONARY ARTERY DISEASE; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW ZEALAND; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 84907485793     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine 2007; 146: 857-67.
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different bloodpressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet 2003; 362: 1527-35.
4. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
5. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic FunctionA Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American College of Cardiology 2006; 47: 1576-83.
6. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
7. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
8. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. Journal of the American College of Cardiology 2008; 51: 37-45.
9. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) European Heart Journal 2012; 33: 1635-701.
10. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal 2003; 326: 1419.
11. Jackevicius CA, Li P, Tu JV. Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction. Circulation 2008; 117: 1028-36.
12. Euroaspire I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995-1001.
13. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. European Heart Journal 2006; 27: 1153-8.
14. Sanfelix-Gimeno G, Peiro S, Ferreros I, et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain. J Manage Care Pharm 2013; 19: 247-57.
15. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376, 162 patients. American Journal of Medicine 2012; 125: 882-7. e1.
16. Thornley S, Marshall R, Chan WC, et al. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event. European Journal of Preventive Cardiology 2012; 19: 349-57.
17. Glader E-L, Sjölander M, Eriksson M, Lundberg M. Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke. Stroke 2010; 41: 397-401.
18. Asberg S, Henriksson KM, Farahmand B, et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14, 529 patients in the Swedish Stroke Register. Stroke 2010; 41: 1338-42.
19. Salmond C, Crampton P, Atkinson J. NZDep2006 Index of Deprivation Users Manual. Department of Public Health, Wellington School of Medicine and Health Sciences, 2007.
20. Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular Outcomes. Circulation 2009; 119: 3028-35.
21. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with highdosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-14.
22. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32, 225 diabetic and nondiabetic patients. Clin Ther 2007; 29: 1761-70.
23. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Canadian Journal of Cardiology 2012; 28: 574-80.
24. Kerr AJ, McLachlan A, Furness S, et al. The burden of modifiable cardiovascular risk factors in the coronary care unit by age, ethnicity, and socioeconomic status-PREDICT CVD-9. New Zealand Medical Journal 2008; 121: 20-33.
25. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
26. Lewey J, Shrank WH, Bowry ADK, et al. Gender and racial disparities in adherence to statin therapy: a meta-analysis. American Heart Journal 2013; 165: 665-78.
27. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Annals of Internal Medicine 2009; 150: 858-68.
28. Grey C, Jackson R, Wells S, et al. Maintenance of statin use over 3 years following acute coronary syndromes: a national data linkage study (ANZACS-QI-2). Heart 2014.
29. Wallach-Kildemoes H, Andersen M, et al. Adherence to preventive statin therapy according to socioeconomic position. Eur J Clin Pharmacol 2013; 69: 1553-63.
30. Niu S, Zhao D, Zhu J, et al. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. American Heart Journal 2009; 157: 709-15. e1.
31. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington, New Zealand2003.
32. Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Medical Care 2006; 44: 471-7.
33. Arnold SV, Spertus JA, Masoudi FA, et al. Beyond Medication Prescription as Performance MeasuresOptimal Secondary Prevention Medication Dosing After Acute Myocardial Infarction. Journal of the American College of Cardiology 2013; 62: 1791-801.
34. Ministry of Health and University of Otago. Decades of disparity III: ethnic and socioeconomic inequalities in mortality, New Zealand 1981-1999. Wellington: Ministry of Health; 2006.
35. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. New England Journal of Medicine 2007; 356: 1503-16.
36. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. New England Journal of Medicine 2010; 362: 1553-5.